Audrey Thomas-Schoemann
Overview
Explore the profile of Audrey Thomas-Schoemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inouri T, Noel J, Blanchet B, Thomas-Schoemann A
Support Care Cancer
. 2024 Sep;
32(10):648.
PMID: 39254772
Concomitant direct oral anticoagulants (DOACs) and tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (anti-VEGF TKI) have been associated with a higher risk of bleeding. Nevertheless, concomitant administration seems...
2.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, et al.
Eur J Clin Pharmacol
. 2023 Mar;
79(5):635-641.
PMID: 36951965
Purpose: Pemetrexed has shown efficacy as monotherapy or in combination with platinum salts in the treatment of non-small cell lung cancer and mesothelioma. However, severe hematological toxicities induced by pemetrexed-based...
3.
Monribot A, Huillard O, Khoudour N, Preta L, Blanchet B, Cabanes L, et al.
Br J Clin Pharmacol
. 2023 Jan;
89(4):1486-1490.
PMID: 36709977
This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity. A 75-year-old man, with no cardiovascular...
4.
Minot-This M, Boudou-Rouquette P, Jouinot A, De Percin S, Balakirouchenane D, Khoudour N, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745797
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed...
5.
Bellesoeur A, Gataa I, Jouinot A, Mershati S, Piketty A, Tlemsani C, et al.
Cancer Chemother Pharmacol
. 2021 Jul;
88(4):741-751.
PMID: 34304283
Background: The risk of drug-drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the...
6.
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, et al.
Cancer Treat Rev
. 2020 Jul;
88:102063.
PMID: 32623296
The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply...
7.
Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, et al.
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32085544
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1),...
8.
Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, et al.
Eur J Cancer
. 2019 Dec;
124:170-177.
PMID: 31794927
Background: The occurrence of severe, acute limiting toxicity in patients receiving anti-programmed cell death receptor-1 monoclonal antibodies, such as nivolumab, is largely unpredictable. Sarcopenia was found to be associated with...
9.
Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31766292
Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small-cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was to explore the exposure-response relationship...
10.
Noe G, Bellesoeur A, Golmard L, Thomas-Schoemann A, Boudou-Rouquette P, Meyo M, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31159331
In the era of precision medicine, research of biomarkers for identification of responders to nivolumab therapy is a major challenge. Peripheral blood mononuclear cells (PBMC) could be an interesting surrogate...